{"success":true,"data":{"pressRelease":{"id":"5585","rtpr_id":"nGNX7LzPG8","ticker":"GLSI","exchange":"NASDAQ","all_tickers":["GLSI"],"title":"Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing","author":"Globe Newswire","published_at":"2026-04-22T21:00:00.138Z","article_body":"STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences,\nInc. (Nasdaq: GLSI) (the \"Company\"), a clinical-stage biopharmaceutical\ncompany focused on its Phase III clinical trial, FLAMINGO-01, which is\nevaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast\ncancer recurrences, today announced that on April 16, 2026, the Company\nreceived notification from the Listing Qualifications Department of The Nasdaq\nStock Market LLC notifying the Company that, because it has not yet filed its\nAnnual Report on Form 10-K for the fiscal year ended December 31, 2025, the\nCompany is not currently in compliance with Nasdaq Listing Rule 5250(c)(1),\nwhich requires timely filing of periodic financial reports with the Securities\nand Exchange Commission. The notice has no immediate effect on the listing or\ntrading of the Company's common stock, which continues to trade on the Nasdaq\nCapital Market under the symbol \"GLSI.\"\n\nThe Company plans to file its Form 10-K for the fiscal year ended December 31,\n2025 as soon as possible, working with both of its auditors where each auditor\nis responsible for their own periods ending in 2024 and 2025.\n\nAbout Greenwich LifeSciences, Inc.\n\nGreenwich LifeSciences is a clinical-stage biopharmaceutical company focused\non the development of GP2, an immunotherapy to prevent breast cancer\nrecurrences in patients who have previously undergone surgery. GP2 is a 9\namino acid transmembrane peptide of the HER2 protein, a cell surface receptor\nprotein that is expressed in a variety of common cancers, including expression\nin 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or\nover-expressor) levels. Greenwich LifeSciences has commenced a Phase III\nclinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences,\nplease visit the Company's website at www.greenwichlifesciences.com and follow\nthe Company's Twitter at https://twitter.com/GreenwichLS.\n\nForward-Looking Statement Disclaimer\n\nStatements in this press release contain \"forward-looking statements\" that are\nsubject to substantial risks and uncertainties. All statements, other than\nstatements of historical fact, contained in this press release are\nforward-looking statements. Forward-looking statements contained in this press\nrelease may be identified by the use of words such as \"anticipate,\" \"believe,\"\n\"contemplate,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"seek,\" \"may,\"\n\"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"target,\" \"aim,\" \"should,\"\n\"will,\" \"would,\" or the negative of these words or other similar expressions,\nalthough not all forward-looking statements contain these words.\nForward-looking statements are based on Greenwich LifeSciences Inc.'s current\nexpectations and are subject to inherent uncertainties, risks and assumptions\nthat are difficult to predict, including statements regarding the intended use\nof net proceeds from the public offering; consequently, actual results may\ndiffer materially from those expressed or implied by such forward-looking\nstatements. Further, certain forward-looking statements are based on\nassumptions as to future events that may not prove to be accurate. These and\nother risks and uncertainties are described more fully in the section entitled\n\"Risk Factors\" in Greenwich LifeSciences' Annual Report on the most recent\nForm 10-K for the year ended December 31, 2024, and other periodic reports\nfiled with the Securities and Exchange Commission. Forward-looking statements\ncontained in this announcement are made as of this date, and Greenwich\nLifeSciences, Inc. undertakes no duty to update such information except as\nrequired under applicable law.\n\nCompany Contact\nSnehal Patel\nInvestor Relations\nOffice: (832) 819-3232\nEmail: info@greenwichlifesciences.com\n\nInvestor & Public Relations Contact for Greenwich LifeSciences\nDave Gentry\nRedChip Companies Inc.\nOffice: 1-800-RED CHIP (733 2447)\nEmail: dave@redchip.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e0bfd967-b05f-43d2-91b4-d2a5d551df99)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7LzPG8","title":"Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing","author":"Globe Newswire","ticker":"GLSI","created":"2026-04-22T21:00:00.138Z","tickers":["GLSI"],"exchange":"NASDAQ","article_body":"STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences,\nInc. (Nasdaq: GLSI) (the \"Company\"), a clinical-stage biopharmaceutical\ncompany focused on its Phase III clinical trial, FLAMINGO-01, which is\nevaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast\ncancer recurrences, today announced that on April 16, 2026, the Company\nreceived notification from the Listing Qualifications Department of The Nasdaq\nStock Market LLC notifying the Company that, because it has not yet filed its\nAnnual Report on Form 10-K for the fiscal year ended December 31, 2025, the\nCompany is not currently in compliance with Nasdaq Listing Rule 5250(c)(1),\nwhich requires timely filing of periodic financial reports with the Securities\nand Exchange Commission. The notice has no immediate effect on the listing or\ntrading of the Company's common stock, which continues to trade on the Nasdaq\nCapital Market under the symbol \"GLSI.\"\n\nThe Company plans to file its Form 10-K for the fiscal year ended December 31,\n2025 as soon as possible, working with both of its auditors where each auditor\nis responsible for their own periods ending in 2024 and 2025.\n\nAbout Greenwich LifeSciences, Inc.\n\nGreenwich LifeSciences is a clinical-stage biopharmaceutical company focused\non the development of GP2, an immunotherapy to prevent breast cancer\nrecurrences in patients who have previously undergone surgery. GP2 is a 9\namino acid transmembrane peptide of the HER2 protein, a cell surface receptor\nprotein that is expressed in a variety of common cancers, including expression\nin 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or\nover-expressor) levels. Greenwich LifeSciences has commenced a Phase III\nclinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences,\nplease visit the Company's website at www.greenwichlifesciences.com and follow\nthe Company's Twitter at https://twitter.com/GreenwichLS.\n\nForward-Looking Statement Disclaimer\n\nStatements in this press release contain \"forward-looking statements\" that are\nsubject to substantial risks and uncertainties. All statements, other than\nstatements of historical fact, contained in this press release are\nforward-looking statements. Forward-looking statements contained in this press\nrelease may be identified by the use of words such as \"anticipate,\" \"believe,\"\n\"contemplate,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"seek,\" \"may,\"\n\"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"target,\" \"aim,\" \"should,\"\n\"will,\" \"would,\" or the negative of these words or other similar expressions,\nalthough not all forward-looking statements contain these words.\nForward-looking statements are based on Greenwich LifeSciences Inc.'s current\nexpectations and are subject to inherent uncertainties, risks and assumptions\nthat are difficult to predict, including statements regarding the intended use\nof net proceeds from the public offering; consequently, actual results may\ndiffer materially from those expressed or implied by such forward-looking\nstatements. Further, certain forward-looking statements are based on\nassumptions as to future events that may not prove to be accurate. These and\nother risks and uncertainties are described more fully in the section entitled\n\"Risk Factors\" in Greenwich LifeSciences' Annual Report on the most recent\nForm 10-K for the year ended December 31, 2024, and other periodic reports\nfiled with the Securities and Exchange Commission. Forward-looking statements\ncontained in this announcement are made as of this date, and Greenwich\nLifeSciences, Inc. undertakes no duty to update such information except as\nrequired under applicable law.\n\nCompany Contact\nSnehal Patel\nInvestor Relations\nOffice: (832) 819-3232\nEmail: info@greenwichlifesciences.com\n\nInvestor & Public Relations Contact for Greenwich LifeSciences\nDave Gentry\nRedChip Companies Inc.\nOffice: 1-800-RED CHIP (733 2447)\nEmail: dave@redchip.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e0bfd967-b05f-43d2-91b4-d2a5d551df99)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-22T21:00:00.175810331Z","server_sent_at_ms":1776891600175},"received_at":"2026-04-22T21:00:00.542Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}